Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma
| Autor: | Stefanie Porkert, Pamela Mai, Constanze Jonak, Felix Weihsengruber, Klemens Rappersberger, Wolfgang Bauer, Ingrid Simonitsch-Klupp, Markus Raderer, Julia Valencak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Acta Dermato-Venereologica, Vol 101, Iss 2, p adv00383 (2021) |
| Druh dokumentu: | article |
| ISSN: | 0001-5555 1651-2057 00015555 |
| DOI: | 10.2340/00015555-3746 |
| Popis: | Systemic monotherapy with rituximab is a well-known treatment approach for primary cutaneous follicle centre lymphoma and primary cutaneous marginal zone lymphoma. Both have excellent prognosis despite high relapse rates. To investigate the long-term effectiveness and clinical outcome of intravenous rituximab at a dose of 375 mg/m2 once weekly, data for 26 patients (17 primary cutaneous follicle centre lymphoma and 9 primary cutaneous marginal zone lymphoma) were analysed retrospectively. Complete remissions occurred in 20 (77%) and partial remissions in 6 patients (23%), demonstrating an overall response rate of 100%. The relapse rate was 52.9% in primary cutaneous follicle centre lymphoma and 88.9% in primary cutaneous marginal zone lymphoma. Ongoing complete remissions after therapy with rituximab were observed in 9 patients (34.6%) with a median progression-free survival of 161 months (13.4 years). These results confirm that intravenous rituximab is an effective and well-tolerated treatment with durable responses in a relevant percentage of patients at a median follow-up of 148 months (12.3 years). |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|